TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: Business Wire
Drug developers & researchers can now leverage the CleanScribe enzyme to reduce dsRNA formation by up to 85% in mRNA synthesis without compromising mRNA yield, capping efficiency, or integrity SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production. The new product reduces dsRNA by up to 85%, helping to develop safer, more potent mRNA therapeutics.CleanScribe RNA Polymerase is a novel DNA-dependent RNA polymerase that catalyzes the in vitro transcription (IVT) of a recombinant gene regulated by the T7 promoter. During the IVT reaction, dsRNA can be produced as a byproduct, which can trigger undesirable inflammatory responses in host cells. The CleanScribe enzyme drastically reduces dsRNA formation during IVT by up to 85% compared to wild-type T7 RNA Polymerase.“In this era of mRNA-based medicine, drug devel
Show less
Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase [Yahoo! Finance]Yahoo! Finance
- Cygnus Technologies and TriLink BioTechnologies® Collaborate to Launch AccuRes™ Host Cell DNA Quantification Kits [Yahoo! Finance]Yahoo! Finance
- Cygnus Technologies and TriLink BioTechnologies® Collaborate to Launch AccuRes™ Host Cell DNA Quantification KitsBusiness Wire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $10.00 price target on the stock.MarketBeat
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $15.00 price target on the stock.MarketBeat
MRVI
Earnings
- 8/7/24 - Beat
MRVI
Sec Filings
- 9/12/24 - Form 8-K
- 8/8/24 - Form 10-Q
- 8/7/24 - Form 8-K
- MRVI's page on the SEC website